SITC Workshop – Focus on the Target: The Tumor Microenvironment


The development of cancer has historically been attributed to genomic alterations of normal host cells, with cancer treatments historically targeting the malignant cell itself. It is now clear that tumor growth and development is a complex process that involves both malignant transformation and the influence of normal host cells, including fibroblasts, endothelial cells, lymphocytes, monocytes, and macrophages. The tumor microenvironment has emerged as a critical target for cancer diagnosis, prognosis, and therapy.

This two-day workshop on the tumor microenvironment will include presentations from thought leaders in the field and cover topics from basic tumor immunobiology to clinical immunotherapy trials that incorporate agents that modulate the tumor microenvironment. It will end with a presentation of progress on the development of the Immunoscore- an ongoing initiative to promote the incorporation of an analysis of immune infiltrates within primary tumors as part of their standard pathologic evaluation for cancer diagnosis, prognosis, and therapy.


The audience for this program is basic scientists and clinical investigators from academic institutions, industry, and regulatory agencies. The audience includes clinicians, translational and basic researchers, graduate students, and postdoctoral fellows involved in cancer research.


- Critically review the role of the immune system in cancer growth and progression and in cancer control and therapy.
- Identify the distinct cellular and molecular components of the tumor microenvironment and how they interact in positive and negative ways with the host immune system.
- Explore current data on the intersection of inflammation and immune infiltrates within the tumor site, defining mechanisms of immune cell trafficking, and identifying opportunities for therapeutic manipulation to improve immune-based therapies.
- Discuss strategies for manipulating cells within the tumor microenvironment, including T cells, myeloid-derived suppressor cells, and other inflammatory cells, to promote tumor regression.
- Review approaches for characterizing and monitoring immune responses within the tumor microenvironment, including novel imaging techniques, and innovative epigenetic and genomic technologies for profiling therapeutic responses.
- Present what has been learned from successful clinical interventions that target the tumor microenvironment to enhance tumor immunity and highlight how to build on these observations to further improve cancer outcomes.
- Discuss the progress, opportunities, and challenges involved in developing the immune score as one standard component of the pathologic evaluation of newly diagnosed cancers.


Upon completion of this program, the participants will be able to:

- Summarize how the immune system can promote evolving malignancies and, conversely, how it can control cancers and be harnessed for therapeutic benefit.
- Explain the details of how a variety of cellular constituents and signaling pathways within the tumor microenvironment collaborate to promote tumor growth or regression.
- Describe how immune cells gain access to tumors and how they can be characterized with new imaging techniques and measured with new technologies for both predicting and profiling responses.
- Interpret the current rationale and clinical strategies for both profiling and therapeutically targeting the tumor microenvironment within cancer patients.
- Describe the features and clinical relevance of the immune score and the challenges involved in harmonizing the methods and evaluation of immune infiltrates to facilitate the incorporation of the immune score into the standard pathologic evaluation of newly diagnosed tumors.

+ show speakers and program
Ivan Borello, MD
Johns Hopkins University School of Medicine

Philippe Bousso, PhD

Vincenzo Bronte, MD
University of Verona

Laurence J.N. Cooper, MD, PhD
MD Anderson Cancer Center

George Coukos, MD, PhD
University of Pennsylvania Medical Center

Pierre G. Coulie, MD, PhD
De Duve Institute and University of Louvain

Mary L. Disis, MD
University of Washington

Glenn Dranoff, MD
Dana-Farber Cancer Institute

Leisha A. Emens, MD, PhD
Johns Hopkins University

Dean W. Flesher, MD, PhD
Stanford University School of Medicine

Bernard A. Fox, PhD
Earle A. Chiles Research Institute

Dmitry I. Gabrilovich, MD, PhD
H. Lee Moffitt Cancer Center and Research Institute

Thomas F. Gajewski, MD, PhD
University of Chicago

Jerome Galon, PhD
INSERM- Cordeliers Research Center

Nicholas Gascoigne, PhD
The Scripps Research Institute

Ulrich Hoffmueller, MBA, PhD
Epiontis GmbH

Samir N. Khleif, MD
Georgia Health Sciences

Alessandro Lugli, MD
Institut of Pathology University of Bern

Francesco Marincola, MD
National Institutes of Health

David H. Munn, MD
Georgia Health Sciences University

Drew M. Pardoll, MD, PhD
Johns Hopkins University School of Medicine

Nicholas P. Restifo, MD
National Cancer Institute

Antoni Ribas, MD
UCLA Medical Center

Brian I. Rini, MD
Cleveland Clinic Taussig Cancer Center

Hans Schreiber, MD, PhD
University of Chicago

Samuel C. Silverstein, MD
Columbia University

Weiping Zou, MD, PhD
University of Michigan

24 Oct - 25 Oct 2012

North Bethesda, MD
United States of America
meeting website